ImmunoGen (NASDAQ:IMGN – Get Rating) and CohBar (NASDAQ:CWBR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares ImmunoGen and CohBar's top-line revenue, earnings per share and valuation.

CohBar has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than CohBar, indicating that it is currently the more affordable of the two stocks.

Profitability

Risk & Volatility

ImmunoGen has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, CohBar has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for ImmunoGen and CohBar, as reported by MarketBeat.

ImmunoGen presently has a consensus target price of $9.80, suggesting a potential upside of 80.15%. CohBar has a consensus target price of $2.50, suggesting a potential upside of 1,566.67%. Given CohBar's stronger consensus rating and higher probable upside, analysts plainly believe CohBar is more favorable than ImmunoGen.

Insider & Institutional Ownership

95.6% of ImmunoGen shares are owned by institutional investors. Comparatively, 7.9% of CohBar shares are owned by institutional investors. 3.3% of ImmunoGen shares are owned by company insiders. Comparatively, 6.5% of CohBar shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

CohBar beats ImmunoGen on 9 of the 13 factors compared between the two stocks.

About ImmunoGen

(Get Rating)

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

About CohBar

(Get Rating)

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.